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The complete synthesis of the C-terminal 28 residues segment 67-94 af human seminal plasma /?-Inhibin, 
called /I,-Inhibin, is reported. The Inhibin-like activity of the native 94 amino acids /Mnhibin is compared 
to that of the synthetic replica of &-Inhibin. In all assays used both peptides effectively suppress the FSI-I 
release induced by LHRH but have little effect on the LH release. In the mouse both peptides are equipotent 
on a mole basis. In the rat the synthetic &-Inhibin is 3-10 times more potent than /l-Inhibin. Both peptides 
are active in rat anterior pituitary primary culture assays where maximum suppression of FSH release in- 
duced by LHRH occurs around 300 pmol/ml of &-Inhibin. In contrast, maximum suppression of FSH 
release in the mouse pituitary assay occurs at IO-15 pmol/ml of either Inhibin. 
1. INTRODUCTION 
In 1932, McCullagh [l] postulated that a 
testicular factor, later called ‘Inhibin’, causes the 
disappearance of ‘castration cells’ in the pituitary 
following its administration to the animal. This 
Inhibin-like activity, causing the selective suppres- 
sion of pituitary follicle-stimulating hormone 
(FSHJ, was subsequently detected in various 
gonadal fluids from both sexes in a number of dif- 
ferent species [2-45 During the last 10 years, 
polypeptides exhibiting Inhibin-like activities were 
detected in human seminal plasma [5,6] and the 
amino acid sequence of a small basic peptide has 
been recently described [7,8]. The complete amino 
acid sequence of another human seminal plasma 
protein containing 94 amino acids has also been 
reported 191. This polypeptide, named B-Inhibin, 
was shown to contain a very basic C-terminal seg- 
ment and preliminary data on its Inhibin-like ae- 
tivity allowed the postulation that this C-terminal 
28 residues segment contains the active core for 
FSH inhibition [9]. Later, in an independent 
report, Johansson et al. [lo] described the se- 
quence of a peptide identical to /?-Inhibin and 
observed that this structure is almost identical to 
that of a human sperm-coating antigen [l l] a Based 
on this sequence identity, it was proposed that ,& 
Inhibin functions might also include its ability to 
act as a sperm coating antigen. 
In this report, we describe in detail the 
characterization of the Inhibin-Iike activity of a 
synthetic replica of the C-terminal 28 residues eg- 
ment of &Inhibin, called Pz-Inhibin. Comparison 
of the activity of p- and flz-Inhibin was done in 
vitro using either the mouse/rat pituitary assay or 
the rat pituitary anterior lobe cell culture assay. 
Results show that both Inhibins are equipotent on 
a mole basis in the mouse pituitary assay. In con- 
trast, in the rat, both in pituitary and cell culture 
assays,~2-Inhibin is 3-IQ-fold more potent than& 
Inhibin. In all assays the levels of luteinizing hor- 
mone {LH) are not significantly affected by either 
Inhibin. 
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2, MATERIALS AND METHODS 
The 94 amino acid @Inhibin was purified as 
previously described [121. The final purification of 
,&Inhibin by reverse-phase HPLC using a p- 
Bondapak C-18 column (Waters) eluted with an 
acetonitrile/O, 1% trifluoroacetic acid (TFA) gra- 
dient is similar to the procedure used for the 
purification of its reduced and carboxymethylated 
(CM) derivative shown in fig.1. Both ,&Inhibin 
and EMU-~nhibin tend to absorb to the C-18 col- 
umn, unless the peptides are first dissolved in 6 M 
guanidine-HCl prior to injection onto the HPLC 
column. Recoveries under these conditions are of 
the order of 70-80%. 
The chemical synthesis of ,&.-Inhibin with the 
proposed disulfide bridge was carried out by 
classical solid-phase peptide synthesis using Boc- 
isoleucine esterified to chloromethylated polysty- 
rene crosslinked with 2% divinylbenzene as an 
anchor group. Chain elongation was performed on 
an automatic peptide synthesizer (Peptomat 82) 
using the classical TFA symmetrical anhydride 
cycle. A 40% concentration of TFA in dichlorome- 
thane containing 0.1% acetyltryptophan added as 
a t-butyl cation scavenger was used. Maximal side 
chain protection was used: Bzl ether for Ser and 
Thr; Bzl esters for Asp and Glu; dichloro-CBZ for 
Lys and Tyr; and acetamidomethyl for Cys. Each 
coupling step was monitored for completion with 
a ninhydrin test and couplings were repeated if 
necessary. If after 1 h at recoupling some free 
amine groups were present, the peptide was 
acetylated. Couplings after Lys 19 were performed 
in 20% DMF in dichloromethane, and all cou- 
plings after Be 10 were performed in 50% DMF. 
After completion of the sequence, the side chain 
protecting groups (with the exception of Cys), were 
cleaved simultaneously together with the ester link 
to the support by liquid HF in the presence of 
0.25oi;o acetyltryptophan and 10% anisole. The 
product was finally subjected to gel filtration of 
LH20 and subsequently purified by two pre- 
parative HPLC (2 x 25 cm, 30,~“C-18) runs using 
l&-40% acetonitrile gradient in 0.25 M NH&AC 
and 7.5% propanol at pH 8.0, and then at pH 6.0. 
Peptide fractions were collected and identified by 
both amino acid composition and sequence. Sub- 
sequentiy, 2.5 mg of the correct peptide was 
treated with mercury acetate to depratect he Cys 
58 
residues, followed by gaseous hydrogen sulfide to 
precipitate the mercury, and finally by exposure to 
air in dilute NH&Ac to allow cyclisation to occur. 
2.1. Whole mouse/rat pituitary assays 
In this assay, different concentrations of either 
P- or &--Inhibins (calculated from quantitative 
amino acid analysis) were preincubated with whole 
pituitaries dissected from 20 day old animals. The 
preincubation medium contained 0.5 ml Dulbec- 
co’s Modified Eagles (DIME) medium containing 
0.1 % BSA. Following a preincubation period of 
1 h, 3 ng of synthetic LHRH in OS ml of medium 
was added, giving a final incubation volume of 
I ml. Incubations were then continued for 3 h at 
37°C in a 95% 02/5% CO2 atmosphere. The 
amount of FSH and LH released into the medium 
was measured using a specific radio-receptor assay 
[13] employing highly purified ovine FSH and LH 
as standards. 
The cell cuitures were obtained from the anterior 
pituitaries of 36-day-old male rats by a 25 min col- 
iagenase/DNase digestion. Cells were then washed 
twice with DME medium containing 0.1% BSA, 
resuspended in DME medium, and 0.5 ml of the 
suspension (containing 400000-500000 cells/O.5 
ml) was used to coat each well. The cells were then 
cultured for 72 h at 37°C in a 95% 02/50?0 CO2 at- 
mosphere. Following this, the medium was re- 
placed with a fresh one containing serum and the 
cells were incubated for 48 h with various concen- 
trations of either Inhibin. Controfs without In- 
hibin-like peptides were afso made, in order to 
measure both the basaI and non-inhibited LHRH 
stimulated release of LH and FSH. Following the 
48 h incubation time, the cells were washed and in- 
cubated in a serum free medium containing LHRH 
(6 ng/well) for 5 h at 37°C. The levels of LH and 
FSH released into the medium were determined us- 
ing a radioimmunoassay kit supplied by the NIH. 
3. RESULTS 
TriaI experiments tudying the susceptibility of 
@-fnhibin to trypsin digestion indicated that this 
molecule after pu~~cat~on by HPLC was resistant 
to low concentrations of enzyme. in fact, treat- 
ment of the reduced and carboxymethylated form 
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Fig. 1. Reverse-phase HPLC purification of the reduced and carboxymethylated (CM) &Inhibin (A) and the purification 
of peptides generated by a 2 h trypsin digestion of CM-&Inhibin at an enzyme to substrate weight ratio of 1: 50 in 0.1 M 
sodium phosphate buffer (pH 8.0), at 37T (B). A p-Bondapak C-18 column (0.38 x 30 cm) was used. Peptides were 
eluted at room temperature with a flow rate of 1 ml/min using 0.1% trifluoroacetic acid (TFA) and a gradient of 
acetonitrile in 0.1% TFA. The actual acetonitrile gradient used is indicated by a dashed line on each chromatogram. 
The elution position of CM-&Inhibin is shown in (B). 
(CM) of ,&-Inhibin (fig.lA) with trypsin at an en- 
zyme to substrate weight ratio of 1: 50 for 2 h 
resulted in one cleavage at a single ARg occupying 
residue 66 in the ,&-Inhibin structure (fig.2B) [9]. 
The resultant products were the segments l-66 and 
67-94 of ,&Inhibin. The C-terminal segment @?- 
Inhibin 67-94) has been named fiz-Inhibin, and its 
sequence is shown in fig.2 [9]. 
Complete Sequence of beta-2-Inhibin 
1 5 10 
NH2. Ile Phe Lys Lys Gl u Asp Cys Lys Tyr Ile 
20 
Val Val Clu Lys Lys Asp Pro Lys Lys Thr 
25 28 
Cys Ser Val Ser Glu Trp Cly Ile .COOH 
Fig.2. Complete amino acid sequence of L?z-Inhibin with 
the proposed disulfide bridge [9]. 
The possibility that &-Inhibin is the 
physiologically active component of ,!3-Inhibin was 
reinforced by the fact that the first cleavage site by 
trypsin involved a post Gln-Arg in the stretch Lys- 
X-X-X-Gln-Arg of &Inhibin [9], a site similar to 
that found in human pro-somatostatin to produce 
somatostatin-28 [9,14]. Since maturation of pro- 
hormones usually involved cleavage of C-terminal 
to basic residues [ 151, we reasoned that the 
Pz-Inhibin segment of &Inhibin could possess the 
required FSH suppression activity. The complete 
synthesis of &-Inhibin was therefore made by a 
solid-phase approach. However, since the whole p- 
Inhibin structure contains 10 cysteine residues, 
potentially forming 5 disulfide bridges, it was not 
obvious ‘a priori’ whether the 2 Cys residues in 
&-Inhibin would be linked by a disulfide bridge in 
the native molecule. These residues were never- 
theless linked in the synthetic replica, and the 
Inhibin-like activity of the resulting molecule was 
tested. 
59 
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The data on the suppression of the LHRH- 
induced FSH release by either the synthetic 
&Inhibin or the native fi-Inhibin both in the 
mouse or rat are shown in Fig.3. Both peptides 
were shown to inhibit FSH release at the pmoliml 
fevel, but not to appreciably affect the LHRH in- 
duced LH release at similar concentrations. In the 
mouse (fig.3A) both peptides are equipotenf on a 
molar basis with the maximum suppressian 
(SS-W?k) of FSH release observed at 
IO-IS pmol/mI. In the rat, both in the whole 
pituitary assay (fig.3B) or in the anterior pituitary 
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Fig.3. (A$) The effect of human seminal plasma&Inhibin and syntheticrl?l-Inhibin on FSH and LH release by LHRH 
stimulated mouse (A) and rat (B) whole pituitaries. The bar graphs represent &he control incubation medium Xevets of 
FSN aad IX, and the levels of the latter in the medium after the addition of 3 ng of LHRH. Each point on the graph 
represents the mean & SE ~ncentrat~o~ of FSR and LH released into the medium obtained by duplicate at&y& from 
at Ieast 5 different pitnitaries f = 5). Both the ~a~ve~-~nhib~n and the sy~l~tic &-&h&in had no effect on the specific 
FSN and LH radio-receptor assays used, The concentrations of aIf Inhibit stock s&&ions were determined by 
~u~~titat~ve amino acid composition. (C) The effect of human seminal &&ma ,&Inhibin and synthetic ~Z-I~~~bi~ on
the ievels of FSH and LH reteased into the medium following stimulation by LHRH in rat anterior pituitary cell 
cultures, The levels of FSH and LH were determined using a radioimmunoassay kit supplied by the NIM. Each point 
an the graph represents the mean f SE af FSH and LH concentrations in the medium obtained by duplicate 
measurements from at least 3 wells. 
cell culture assay (fig.3C) 20-40 times higher con- 
ce~t~atio~s of either peptide were needed to 
achieve ~-~~~~ maximal FSH ~~~ib~~~~n. fn con- 
trast to the e~~~~~~c~ rtbscrved in the mCWse* 
~~~I~~bin was found to be more potent than @ 
Inhibin in the rat. The exact value is difficult to 
calculate in view of the non-parallellism of the in- 
hibition curves, but it can vary between 3-10 times 
higher in potency (figJB,C). Within eke sensitivity 
of the assay the effect of both peptides on the basal 
release of FSH could not be accurateiely estimated, 
but was found to be less than the one observed in 
the presence of LHRH in the incubation medium. 
Interestingly, in a~1 these in vitro assays, the ef- 
fect of both peptides on FSH secretion is ckady 
biphasic (fig.3A-C). In other words, at higher 
concentrations of either fnhibin, the s~p~~ess~o~ 
of FSH release is less effective than at lower con- 
centrations, Wuwever, this effect has not been 
observed in vivo with @-fnhibin [9]. 
When mouse pituitaries were Simu~t~~eousIy ex- 
posed to either B-Inhibin (13 pmolknl) or 
&Inhibin (10 pmol/ml) in the presence of 
3 ng/ml of LHRH for different time intervals, the 
release of FSH, but not LH, was significantly 
lower than the LHRH control values at all times up 
to 12 h (aot shown). In this experiment of 
cumulative release of FSH, both peptides were 
equipotent, in agreement with fig.%% 
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The results presented in this work, indicate that 
the C-terminal 28 residues of P-Inhibin 
l&-Inhibin), contain the active core for the sup- 
pression of pituitary FSH release induced by 
LHRH. Furthermore, based on this activity it is 
proposed that the Cys, and Cyszt of ,&Inhibin 
(f&Z) are linked by a disulfide bridge in the native 
@-Inhibin. Rigorous proof of the latter will have to 
await complete disulfide bond ~si~~ment in the 
whole native ~-Inhib~n. In view of the presence of 
three pairs of Lys-Lys residues within the 
fiz-Inhibin sequence (fig.& and the known 
cleavage of pro-hormones at these sites {IS], it 
would not be astonishing if further shortening of 
this peptide, either at the N- or C-terminus could 
still produce an active molecule. However, this 
would have to be confirmed by a systematic 
structure-activity study of this polypeptide. Never- 
theless, the data presented here paint out that the 
N-terminal 66 residues of &Inhibin [9] are ap- 
p~re~ti~ not necessary for eliciting the observed 
I~~ib~-l~ke activity. A similar finding of an W- 
terminal extension not necessary for biological ac- 
tivity was observed previously for another pro- 
hormone, pronatriodilatin [ 16,173 containing 
within its C-terminus the active atria1 natriuretic 
factor [Xc;], 
The potency of either /3- or ,&-Inhibin observed 
in this study, suggests that both human peptides 
when used in the rat pituitary cell culture assay are 
~~im~lIy active in the l-2 pg/ml concentration. 
Since the assays used invoIved the i~cnbation of a 
human peptide with either mouse or rat pituitar~es~ 
the ~ossi~~ty of sequence variations of the active 
factor between species should bc considered. 
Accordingly, the potency observed in our assays 
might not reflect the intrinsic Inhibin-like activity 
of this peptide in a homologous assay. The results 
presented here should permit a standardization of 
the assays with pure synthetic preparations in 
order to assess the real physiological involvement 
of either la- or &-Inhibin in viva. 
Various reports have appeared in the literature 
showing that impure preparations of either bovine, 
porcine, or ovine fo~i~I~ fluids cause a suppres- 
sion of FSH r&ease induced by LHRH in primary 
pituitary cell cu&ures in the mg/mi dose range 
[l&20]. Recent data on purified fractions of 
62 
either porcine 12 it or bovine f22] f~~~i~~~Iar f&id 
show that “Inhibin” migrate on SDS-PAGE with 
apparent !& values of 14OW or 65000, respective- 
ly. The maximal activity of these ovarian Inhibin 
preparations is of the order of 60-70 ng/ml in the 
cell culture assay [21]. It is therefore possible that 
other Inhibin-like substances exist in gonadal ex- 
tracts which could be more active than either ,&- or 
,&-Inhibin, However, in view of the variability bet- 
ween the assays used in various Iaboratories fur- 
ther work needs to be done for comparative activi- 
ty purposes, ~urthermore~ the sensitivity of In- 
hibin pre~~at~ons to organic solvents [23] is a fac- 
tor to consider when reverse-phase HPLC is used 
as a final purification method. 
The biphasic nature of the inhibition of FSH 
found in the in vitro assays used in this work is 
puzzling. This phenomenon was also observed in 
the same mouse or rat pituitary assays using a dif- 
ferent 31 amino acid Inhibin-like peptide f&24]. 
This biphasic phenomenon does not seem to be 
specific to I~h~b~n-I~ke substances isolated from 
males, since a similar observation has been 
reported with porcine follicular fluid preparations 
!25]. The reason for the biphasic response, which 
is not always observed with all Xnhibin-like 
preparations [26] is not well understood at the mo- 
ment. It is possible that this phenomenon is related 
to the incubation conditions, since in viva this ef- 
fect is not observed with ,&Inhibin [9]. 
The almost complete homology of the ,&Inhibin 
structure 19) with that of a sperm-coating antigen 
[l&I lf, and the presence of this peptide in large 
quantities in either prostate [f ff or gastric secre- 
tions 1271 suggest hat & or ~~-In~ibj~ might, in 
addition to causing FSH suppr~s~on~ have a more 
general function. Future tests using oligonuc- 
leotide probes and ‘in situ’ hybridization would be 
helpful in defining the various sites of synthesis of 
P-Inhibin, and will be a step towards under- 
standing the physiology of this novel series of 
human seminal plasma peptides. 
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